Generative adversarial network: An overview of theory and applications

Abstract In recent times, image segmentation has been involving everywhere including disease diagnosis to autonomous vehicle driving. In computer vision, this image segmentation is one of the vital works and it is relatively complicated than other vision undertakings as it needs low-level spatial data. Especially, Deep Learning has impacted the field of segmentation incredibly and gave us today different successful models. The deep learning associated Generated Adversarial Networks (GAN) has presenting remarkable outcomes on image segmentation. In this study, the authors have presented a systematic review analysis on recent publications of GAN models and their applications. Three libraries such as Embase (Scopus), WoS, and PubMed have been considered for searching the relevant papers available in this area. Search outcomes have identified 2084 documents, after two-phase screening 52 potential records are included for final review. The following applications of GAN have been emerged: 3D object generation, medicine, pandemics, image processing, face detection, texture transfer, and traffic controlling. Before 2016, research in this field was limited and thereafter its practical usage came into existence worldwide. The present study also envisions the challenges associated with GAN and paves the path for future research in this realm

Brolucizumab-associated intraocular inflammation in Indian patients by VRSI study group

Context: Concerns about brolucizumab’s (Pagenax®) association with intraocular inflammation (IOI) limit its use despite its cost-effectiveness and efficacy. This multicentric study analyzes IOI incidence across 21 tertiary eyecare centers in India since its introduction in October 2020. Purpose: To determine the real-world incidence rate of IOI in Indian patients secondary to intravitreal brolucizumab across 21 tertiary eye care centers in India. Settings and Design: Retrospective multicentric, survey-based study. Methods: Data including number of patients treated, clinical indications, side effects encountered, and IOI case details was collected via Google Forms in 21 Indian tertiary eye care centers since October 2020. Mean, median, frequency, and standard deviation were calculated for statistical analysis. Results: All centers used pro re nata protocol for brolucizumab injections with a minimum injection interval of 8 weeks. The incidence of IOI was 0.79% (21 events out of 2655 eyes). Treatment indications included idiopathic polypoidal choroidal vasculopathy, neovascular age-related macular degeneration, diabetic macular edema, and off-label uses. IOI was experienced after the first injection (57%) in majority of cases with a median onset of 14 days (range: 1–65 days). IOI was mild in 28.5%, moderate in 33%, and severe in 38% of cases. Eighteen out of 21 IOI eyes recovered preinjection best corrected visual acuity or better. Conclusions: Our study found a lower IOI incidence (0.79%) with brolucizumab (Pagenax) in Indian patients compared to previously reported literature. IOI events were mostly mild to moderate, and post-treatment, most patients improved or maintained BCVA. Larger prospective multicentric studies with PRN dosing protocol are needed to confirm these findings